Author: admin

DelveInsight’s “EGFR Inhibitors-Induced Skin Disorders Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology as well as the EGFR Inhibitors-Induced Skin Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the EGFR Inhibitors-Induced Skin Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR Inhibitors-Induced Skin Disorders Market Forecast

Some of the key facts of the EGFR Inhibitors-Induced Skin Disorders Market Report: 

• The EGFR Inhibitors-Induced Skin Disorders market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In October 2024, Lutris Pharma completed patient enrollment in its Phase II clinical trial of LUT014, a novel B-Raf inhibitor for topical use aimed at treating acneiform rash caused by epidermal growth factor receptor (EGFR) inhibitor therapy. The study enrolled 117 patients with metastatic colorectal cancer (mCRC) who developed Grade 2 or non-infected Grade 3 acneiform rash induced by EGFR inhibitors.

• In February 2024, The US FDA awarded Orphan Drug Designation (ODD) to LUT014 for addressing EGFR inhibitor-induced acneiform rash.

• In January 2023, The FDA approved an investigational new drug (IND) application for HT-001, aiming to treat rash and skin disorders linked with EGFR inhibitor therapy.

• In 2023, the United States had the highest proportion of patients affected by EGFR inhibitor-induced skin disorders among the 7MM.

• In 2023, around 13,000 instances of EGFR inhibitor-induced skin disorders were reported among NSCLC cases in the United States.

• EGFR is mutated in 3.22% of colorectal carcinoma patients, with EGFR mutations occurring in 2.33% of all colorectal carcinoma cases.

• Key EGFR Inhibitors-Induced Skin Disorders Companies: Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others

• Key EGFR Inhibitors-Induced Skin Disorders Therapies: LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others

• The EGFR Inhibitors-Induced Skin Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR Inhibitors-Induced Skin Disorders pipeline products will significantly revolutionize the EGFR Inhibitors-Induced Skin Disorders market dynamics.

EGFR Inhibitors-Induced Skin Disorders Overview

EGFR inhibitors-induced skin disorders refer to dermatological side effects caused by medications that inhibit the epidermal growth factor receptor (EGFR). These drugs are commonly used in the treatment of various cancers, including lung, colorectal, and head and neck cancers. Skin-related adverse effects are among the most common side effects of EGFR inhibitors and can include rash, acneiform eruptions, dry skin, pruritus (itching), and paronychia (inflammation around the nails).

Get a Free sample for the EGFR Inhibitors-Induced Skin Disorders Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/egfr-inhibitors-induced-skin-disorders-market

EGFR Inhibitors-Induced Skin Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

EGFR Inhibitors-Induced Skin Disorders Epidemiology Segmentation:

The EGFR Inhibitors-Induced Skin Disorders market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of EGFR Inhibitors-Induced Skin Disorders

• Prevalent Cases of EGFR Inhibitors-Induced Skin Disorders by severity

• Gender-specific Prevalence of EGFR Inhibitors-Induced Skin Disorders

• Diagnosed Cases of Episodic and Chronic EGFR Inhibitors-Induced Skin Disorders

Download the report to understand which factors are driving EGFR Inhibitors-Induced Skin Disorders epidemiology trends @ EGFR Inhibitors-Induced Skin Disorders Epidemiology Forecast

EGFR Inhibitors-Induced Skin Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR Inhibitors-Induced Skin Disorders market or expected to get launched during the study period. The analysis covers EGFR Inhibitors-Induced Skin Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the EGFR Inhibitors-Induced Skin Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

EGFR Inhibitors-Induced Skin Disorders Therapies and Key Companies

• LUT-014: Lutris Pharma

• HT-001: Hoth Therapeutics

• AC-701 Topical Gel 0.3%: TWi Biotechnology, Inc.

Discover more about therapies set to grab major EGFR Inhibitors-Induced Skin Disorders market share @ EGFR Inhibitors-Induced Skin Disorders Treatment Landscape

EGFR Inhibitors-Induced Skin Disorders Market Strengths

• The rising incidence of cancer patients and access to anti-EGFR treatment over the globe increase chances of occurrence of EGFR inhibitor-induced skin disease and thus the surge in treatment options.

• Emergence of several novel therapy is expected to fuel the market growth.

EGFR Inhibitors-Induced Skin Disorders Market Opportunities

• Limited approved treatment options offer a great opportunity for the investment and development of novel therapies.

• Medications with better safety, effectiveness, and patient compliance are the current unmet need of the anti-EGFR induced skin diseases market.

Scope of the EGFR Inhibitors-Induced Skin Disorders Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key EGFR Inhibitors-Induced Skin Disorders Companies: Lutris Pharma, Hoth Therapeutics, TWi Biotechnology, Inc., and others

• Key EGFR Inhibitors-Induced Skin Disorders Therapies: LUT-014, HT-001, AC-701 Topical Gel 0.3%, and others

• EGFR Inhibitors-Induced Skin Disorders Therapeutic Assessment: EGFR Inhibitors-Induced Skin Disorders current marketed and EGFR Inhibitors-Induced Skin Disorders emerging therapies

• EGFR Inhibitors-Induced Skin Disorders Market Dynamics: EGFR Inhibitors-Induced Skin Disorders market drivers and EGFR Inhibitors-Induced Skin Disorders market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• EGFR Inhibitors-Induced Skin Disorders Unmet Needs, KOL’s views, Analyst’s views, EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement 

To know more about EGFR Inhibitors-Induced Skin Disorders companies working in the treatment market, visit @ EGFR Inhibitors-Induced Skin Disorders Clinical Trials and Treatment

Table of Contents 

1. EGFR Inhibitors-Induced Skin Disorders Market Report Introduction

2. Executive Summary for EGFR Inhibitors-Induced Skin Disorders

3. SWOT analysis of EGFR Inhibitors-Induced Skin Disorders

4. EGFR Inhibitors-Induced Skin Disorders Patient Share (%) Overview at a Glance

5. EGFR Inhibitors-Induced Skin Disorders Market Overview at a Glance

6. EGFR Inhibitors-Induced Skin Disorders Disease Background and Overview

7. EGFR Inhibitors-Induced Skin Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of EGFR Inhibitors-Induced Skin Disorders 

9. EGFR Inhibitors-Induced Skin Disorders Current Treatment and Medical Practices

10. EGFR Inhibitors-Induced Skin Disorders Unmet Needs

11. EGFR Inhibitors-Induced Skin Disorders Emerging Therapies

12. EGFR Inhibitors-Induced Skin Disorders Market Outlook

13. Country-Wise EGFR Inhibitors-Induced Skin Disorders Market Analysis (2020–2034)

14. EGFR Inhibitors-Induced Skin Disorders Market Access and Reimbursement of Therapies

15. EGFR Inhibitors-Induced Skin Disorders Market Drivers

16. EGFR Inhibitors-Induced Skin Disorders Market Barriers

17.  EGFR Inhibitors-Induced Skin Disorders Appendix

18. EGFR Inhibitors-Induced Skin Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR Inhibitors-Induced Skin Disorders Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Lutris Pharma, Hoth Therapeutics, TWi Biotechnology

DelveInsight’s “Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epidermal growth factor receptor-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Epidermal growth factor receptor-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Epidermal growth factor receptor-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; EGFR-Non Small Cell Lung Cancer Market Forecast

Some of the key facts of the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report: 

• The Epidermal growth factor receptor-Non Small Cell Lung Cancer market size was valued ~USD 4,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In July 2024, Delta-Fly Pharma has begun enrolling participants in the Phase III clinical trial of DFP-14323 for treating non-small cell lung cancer (NSCLC). The trial aims to assess the combination of DFP-14323 with a 20mg daily dose of Afatinib, compared to a 40mg daily dose of Afatinib alone. It will enroll stage III/IV NSCLC patients in Japan who have uncommon EGFR mutations.

• In April 2024, ORIC Pharmaceuticals, Inc. has completed the dose escalation phase of the Phase Ib trial for ORIC-114 in patients with advanced solid tumors featuring EGFR and HER2 exon 20 alterations or HER2 amplifications. Based on the results, ORIC has selected two provisional recommended Phase II doses (RP2D) of ORIC-114 at 80 mg and 120 mg QD, which are being further evaluated in three dose expansion cohorts for dose optimization and final RP2D determination. These cohorts have been initiated in patients with non-small cell lung cancer (NSCLC) having EGFR exon 20 (inhibitor-naïve), HER2 exon 20, or atypical EGFR mutations. Additionally, the company has launched an extension cohort for treating first-line, treatment-naïve EGFR exon 20 NSCLC patients.

• In April 2024, Nuvalent, Inc. announced the unveiling of new preclinical data for its innovative HER2-selective inhibitor, NVL-330. The poster showcasing this data was presented at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10 in San Diego.

• In 2023, the total number of incident cases of NSCLC across the 7MM was approximately 524,000, with expectations for this number to rise during the forecast period.

• In 2023, the United States reported nearly 202,500 new cases of NSCLC.

• In 2023, the total number of EGFR NSCLC cases in the EU4 and the UK was estimated to be around 31,200.

• In 2023, the estimated number of EGFR Exon 20 insertion mutation cases in Japan was approximately 6,500.

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Companies: AstraZeneca, J&J Innovative Medicine, Hansoh Pharmaceutical, Cullinan Oncology/Taiho Pharmaceutical, Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies: TAGRISSO, RYBREVANT, Aumolertinib, Zipalertinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others

• The Epidermal growth factor receptor-NSCLC epidemiology based on gender analyzed that in the United States, 7 out of 10 patients had metastatic NSCLC (Stage III b and IV)

• The Epidermal growth factor receptor-Non Small Cell Lung Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epidermal growth factor receptor-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the Epidermal growth factor receptor-Non Small Cell Lung Cancer market dynamics.

Epidermal growth factor receptor-Non Small Cell Lung Cancer Overview

EGFR-Non Small Cell Lung Cancer (EGFR-NSCLC) is a subtype of non-small cell lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene. These mutations lead to abnormal cell growth and division. EGFR-NSCLC is more common in non-smokers, women, and people of East Asian descent.

Get a Free sample for the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report –

https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market

Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology Segmentation:

The Epidermal growth factor receptor-Non Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of EGFR-Non Small Cell Lung Cancer

• Prevalent Cases of EGFR-Non Small Cell Lung Cancer by severity

• Gender-specific Prevalence of EGFR-Non Small Cell Lung Cancer

• Diagnosed Cases of Episodic and Chronic EGFR-Non Small Cell Lung Cancer

Download the report to understand which factors are driving Epidermal growth factor receptor-Non Small Cell Lung Cancer epidemiology trends @ EGFR-Non Small Cell Lung Cancer Epidemiology Forecast

Epidermal growth factor receptor-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epidermal growth factor receptor-Non Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Epidermal growth factor receptor-Non Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Epidermal growth factor receptor-Non Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies and Key Companies

• TAGRISSO: AstraZeneca

• RYBREVANT: J&J Innovative Medicine

• Aumolertinib: Hansoh Pharmaceutical

• Zipalertinib: Cullinan Oncology/Taiho Pharmaceutical

• Telisotuzumab Vedotin(Teliso-V): Abbvie

• Lazertinib (Leclaza): Yuhan Corporation/ Janssen Research & Development)

• Nazartinib (EGF816): Novartis

• Patritumab deruxtecan (HER3-DXd): Daiichi Sankyo

Discover more about therapies set to grab major Epidermal growth factor receptor-Non Small Cell Lung Cancer market share @ EGFR-Non Small Cell Lung Cancer Treatment Market

Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Drivers

• Increasing Use of Biomarker Testing

• Increase in the Mutation Specific Trials Activity and Approval

• Increasing Incidence of NSCLC

• Rich Pipeline and label expansion of approved therapies

Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Barriers

• Cost-Effectiveness of Therapies

• Small Patient Populations for Specific Subsets of NSCLC

• Generic or Biosimilar Erosion

Scope of the Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Companies: AstraZeneca, J&J Innovative Medicine, Hansoh Pharmaceutical, Cullinan Oncology/Taiho Pharmaceutical, Abbvie, Yuhan Corporation, Janssen Research & Development), Novartis, Daiichi Sankyo, and others

• Key Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapies: TAGRISSO, RYBREVANT, Aumolertinib, Zipalertinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others

• Epidermal growth factor receptor-Non Small Cell Lung Cancer Therapeutic Assessment: Epidermal growth factor receptor-Non Small Cell Lung Cancer current marketed and Epidermal growth factor receptor-Non Small Cell Lung Cancer emerging therapies

• Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Dynamics: Epidermal growth factor receptor-Non Small Cell Lung Cancer market drivers and Epidermal growth factor receptor-Non Small Cell Lung Cancer market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Epidermal growth factor receptor-Non Small Cell Lung Cancer Unmet Needs, KOL’s views, Analyst’s views, Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Access and Reimbursement 

To know more about Epidermal growth factor receptor-Non Small Cell Lung Cancer companies working in the treatment market, visit @ EGFR-NSCLC Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Report Introduction

2. Executive Summary for Epidermal growth factor receptor-Non Small Cell Lung Cancer

3. SWOT analysis of Epidermal growth factor receptor-Non Small Cell Lung Cancer

4. Epidermal growth factor receptor-Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance

5. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Overview at a Glance

6. Epidermal growth factor receptor-Non Small Cell Lung Cancer Disease Background and Overview

7. Epidermal growth factor receptor-Non Small Cell Lung Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Epidermal growth factor receptor-Non Small Cell Lung Cancer 

9. Epidermal growth factor receptor-Non Small Cell Lung Cancer Current Treatment and Medical Practices

10. Epidermal growth factor receptor-Non Small Cell Lung Cancer Unmet Needs

11. Epidermal growth factor receptor-Non Small Cell Lung Cancer Emerging Therapies

12. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Outlook

13. Country-Wise Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Analysis (2020–2034)

14. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Access and Reimbursement of Therapies

15. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Drivers

16. Epidermal growth factor receptor-Non Small Cell Lung Cancer Market Barriers

17.  Epidermal growth factor receptor-Non Small Cell Lung Cancer Appendix

18. Epidermal growth factor receptor-Non Small Cell Lung Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EGFR-Non Small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | AstraZeneca, J&J Innovative Medicine, Hansoh Pharma, Cullinan Oncology, Taiho Pharma

DelveInsight’s “Dysmenorrhea Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dysmenorrhea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dysmenorrhea Market Forecast

Some of the key facts of the Dysmenorrhea Market Report: 

• The Dysmenorrhea market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In May 2024, TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare and incurable diseases, announced positive topline results from its Phase 2a clinical trial of Merigolix. This oral gonadotropin-releasing hormone (GnRH) receptor antagonist was tested in patients with moderate to severe endometriosis-associated pain. The trial successfully met its primary endpoint, showing a statistically significant reduction in dysmenorrhea scores compared to placebo across all three dosage groups (120mg p=0.044, 240mg p=0.001, 320mg p<0.001).

• In 2023, the United States held the largest market share for dysmenorrhea, exceeding USD 5 billion, followed by Japan, the EU4 countries, and the UK.

• In the United States, an estimated 52 million cases of primary dysmenorrhea and 6.8 million cases of secondary dysmenorrhea were reported in 2023.

• In 2023, Germany recorded the highest number of dysmenorrhea cases among the EU4 countries, with approximately 13 million cases, while Spain had the lowest, at around 8 million cases.

• Dysmenorrhea affects 50–90% of adolescent girls and women of reproductive age, making it a major cause of absenteeism. Around 25–35% experience severe pain.

• Primary dysmenorrhea typically starts 6–12 months after menarche, aligning with the onset of ovulatory cycles, and commonly recurs with each menstrual cycle.

• Relugolix monotherapy was shown to alleviate pelvic pain in women with endometriosis. When combined with estradiol/norethisterone acetate, it helped prevent relugolix-induced bone mineral density loss. Both the FDA and EMA have approved the fixed-dose combination of relugolix/estradiol/norethisterone (MYFEMBREE/RYEQO).

• Key Dysmenorrhea Companies: ObsEva SA, Fuji Pharma’s, Bayer, Juniper Pharmaceuticals, Inc., Nobelpharma, Laboratorios Andromaco S.A., Boehringer Ingelheim, Organon and Co, Pfizer, Duramed Research, Vantia Ltd, Lianyungang Kanion Group, Ltd., Jiangsu Kanion Pharmaceutical Co, Isifer AB, AbbVie, GlaxoSmithKline, and others

• Key Dysmenorrhea Therapies: Yselty, FSN-013, Acetaminophen, Lidocaine, NPC-16, Meloxicam, EE20/DRSP(BAY86-5300), Meloxicam, Etoricoxib, piroxicam, levonorgestrel, VA111913, Kanion Capsule, KYG0395, Lignocaine, Elagolix, sumatriptan succinate, and others

• The Dysmenorrhea epidemiology based on gender analyzed that more than two-thirds of dysmenorrhea patients reported moderate-to-severe pain

• The Dysmenorrhea market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dysmenorrhea pipeline products will significantly revolutionize the Dysmenorrhea market dynamics.

Dysmenorrhea Overview

In medicine, painful menstrual cycles are referred to as dysmenorrhea, or, to put it more simply, “menstrual cramps.” Two types of dysmenorrhea can be distinguished: Dysmenorrhea in two stages: primary and secondary.

Get a Free sample for the Dysmenorrhea Market Report 

https://www.delveinsight.com/report-store/dysmenorrhea-market

Dysmenorrhea Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dysmenorrhea Epidemiology Segmentation:

The Dysmenorrhea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Dysmenorrhea

• Prevalent Cases of Dysmenorrhea by severity

• Gender-specific Prevalence of Dysmenorrhea

• Diagnosed Cases of Episodic and Chronic Dysmenorrhea

Download the report to understand which factors are driving Dysmenorrhea epidemiology trends @ Dysmenorrhea Epidemiology Forecast

Dysmenorrhea Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dysmenorrhea market or expected to get launched during the study period. The analysis covers Dysmenorrhea market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dysmenorrhea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dysmenorrhea Therapies and Key Companies

• Yselty: ObsEva SA

• FSN-013: Fuji Pharma’s

• Acetaminophen: Bayer

• Lidocaine: Juniper Pharmaceuticals, Inc.

• NPC-16: Nobelpharma

• Meloxicam: Laboratorios Andromaco S.A.

• EE20/DRSP(BAY86-5300): Bayer

• Meloxicam: Boehringer Ingelheim

• Etoricoxib: Organon and Co

• piroxicam: Pfizer

• levonorgestrel: Duramed Research

• VA111913: Vantia Ltd

• Kanion Capsule: Lianyungang Kanion Group, Ltd.

• KYG0395: Jiangsu Kanion Pharmaceutical Co

• Lignocaine: Isifer AB

• Elagolix: AbbVie

• sumatriptan succinate: GlaxoSmithKline

Discover more about therapies set to grab major Dysmenorrhea market share @ Dysmenorrhea Treatment Market

Dysmenorrhea Market Strengths

• Rising prevalence of dysmenorrhea which is attributed to changing lifestyle, addiction to smoking and alcohol, hormonal changes and physical and mental stress will substantially contribute to high growth of the market.

Dysmenorrhea Market Opportunities

• Long term use of current treatment options is not recommended as these options are associated with significant side effects such as loss in bone density seen with hormonal agents; hence there is still scope for long-term safe and effective treatment options.

Scope of the Dysmenorrhea Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dysmenorrhea Companies: ObsEva SA, Fuji Pharma’s, Bayer, Juniper Pharmaceuticals, Inc., Nobelpharma, Laboratorios Andromaco S.A., Boehringer Ingelheim, Organon and Co, Pfizer, Duramed Research, Vantia Ltd, Lianyungang Kanion Group, Ltd., Jiangsu Kanion Pharmaceutical Co, Isifer AB, AbbVie, GlaxoSmithKline, and others

• Key Dysmenorrhea Therapies: Yselty, FSN-013, Acetaminophen, Lidocaine, NPC-16, Meloxicam, EE20/DRSP(BAY86-5300), Meloxicam, Etoricoxib, piroxicam, levonorgestrel, VA111913, Kanion Capsule, KYG0395, Lignocaine, Elagolix, sumatriptan succinate, and others

• Dysmenorrhea Therapeutic Assessment: Dysmenorrhea current marketed and Dysmenorrhea emerging therapies

• Dysmenorrhea Market Dynamics: Dysmenorrhea market drivers and Dysmenorrhea market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dysmenorrhea Unmet Needs, KOL’s views, Analyst’s views, Dysmenorrhea Market Access and Reimbursement 

To know more about Dysmenorrhea companies working in the treatment market, visit @ Dysmenorrhea Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Dysmenorrhea Market Report Introduction

2. Executive Summary for Dysmenorrhea

3. SWOT analysis of Dysmenorrhea

4. Dysmenorrhea Patient Share (%) Overview at a Glance

5. Dysmenorrhea Market Overview at a Glance

6. Dysmenorrhea Disease Background and Overview

7. Dysmenorrhea Epidemiology and Patient Population

8. Country-Specific Patient Population of Dysmenorrhea 

9. Dysmenorrhea Current Treatment and Medical Practices

10. Dysmenorrhea Unmet Needs

11. Dysmenorrhea Emerging Therapies

12. Dysmenorrhea Market Outlook

13. Country-Wise Dysmenorrhea Market Analysis (2020–2034)

14. Dysmenorrhea Market Access and Reimbursement of Therapies

15. Dysmenorrhea Market Drivers

16. Dysmenorrhea Market Barriers

17.  Dysmenorrhea Appendix

18. Dysmenorrhea Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dysmenorrhea Market Expected to Experience Major Growth by 2034, According to DelveInsight | ObsEva SA, Fuji Pharma’s, Bayer, Juniper Pharmaceuticals, Inc., Nobelpharma, AbbVie, GlaxoSmithKline

DelveInsight’s “Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dyslipidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dyslipidemia Market Forecast

Some of the key facts of the Dyslipidemia Market Report: 

• The Dyslipidemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In July 2024, NewAmsterdam Pharma reported positive results from the first of its four pivotal Phase III trials, demonstrating that its lead cardiovascular candidate, obicetrapib, effectively lowers cholesterol levels. The BROOKLYN trial (NCT05425745) is the initial study in NewAmsterdam’s portfolio, focused on assessing obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains inadequately managed despite receiving the maximum tolerated lipid-lowering therapy.

• The most common form of dyslipidemia observed was hypercholesterolemia (total cholesterol level ≥ 5.0 mmol/L), with an average prevalence of 58.2%, ranging from 50% to 67% based on the region.

• The standardized prevalence figures for dyslipidemia in Switzerland, characterized by either self-reported drug use alone or a combination of self-reported drug use and a self-reported diagnosis of dyslipidemia, were 3.7% (95% CI 3.3-4.1%) and 12.2% (95% CI 11.5-12.9%) for women, and 6.3% (95% CI 5.7-6.8%) and 16.9% (95% CI 16.0-17.8%) for men, respectively.

• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others

• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others

• The Dyslipidemia epidemiology based on gender analyzed that females are affected more as compared to males, in case of Dyslipidemia

• The Dyslipidemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dyslipidemia pipeline products will significantly revolutionize the Dyslipidemia market dynamics.

Dyslipidemia Overview

Dyslipidemia is a medical condition characterized by abnormal levels of lipids (fats) in the blood. These abnormalities can include elevated levels of low-density lipoprotein cholesterol (LDL-C, often referred to as “bad” cholesterol), triglycerides, and total cholesterol, as well as low levels of high-density lipoprotein cholesterol (HDL-C, known as “good” cholesterol). Dyslipidemia is a major risk factor for cardiovascular diseases, including coronary artery disease and stroke.

Get a Free sample for the Dyslipidemia Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/dyslipidemia-market

Dyslipidemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dyslipidemia Epidemiology Segmentation:

The Dyslipidemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Dyslipidemia

• Prevalent Cases of Dyslipidemia by severity

• Gender-specific Prevalence of Dyslipidemia

• Diagnosed Cases of Episodic and Chronic Dyslipidemia

Download the report to understand which factors are driving Dyslipidemia epidemiology trends @ Dyslipidemia Epidemiology Forecast

Dyslipidemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dyslipidemia market or expected to get launched during the study period. The analysis covers Dyslipidemia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dyslipidemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dyslipidemia Therapies and Key Companies

• Pemafibrate (K-877): Kowa Company

• AZD8233: AstraZeneca And Parexel

• Rosuvastatin: AstraZeneca

• GW856553: GlaxoSmithKline

• A3309: Albireo

• TA-8995: Xention Ltd

• Alirocumab: Sanofi

• Muraglitazar: Bristol-Myers Squibb

• Atorvastatin (Lipilou): Chong Kun Dang Pharmaceutical

• MK1903: Merck Sharp & Dohme LLC

• Lapaquistat acetate: Takeda

• PPAR alpha: Eli Lilly and Company

Discover more about therapies set to grab major Dyslipidemia market share @ Dyslipidemia Treatment Landscape

Dyslipidemia Market Drivers

• Increasing global geriatric population

• Increase in the prevalence of lifestyle related and cardiovascular disorders

Dyslipidemia Market Barriers

• Significant proportion of treated patients do not reach recommended treatment goal

• Increase in availability of generic drugs

Scope of the Dyslipidemia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others, and others

• Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others

• Dyslipidemia Therapeutic Assessment: Dyslipidemia current marketed and Dyslipidemia emerging therapies

• Dyslipidemia Market Dynamics: Dyslipidemia market drivers and Dyslipidemia market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dyslipidemia Unmet Needs, KOL’s views, Analyst’s views, Dyslipidemia Market Access and Reimbursement 

To know more about Dyslipidemia companies working in the treatment market, visit @ Dyslipidemia Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Dyslipidemia Market Report Introduction

2. Executive Summary for Dyslipidemia

3. SWOT analysis of Dyslipidemia

4. Dyslipidemia Patient Share (%) Overview at a Glance

5. Dyslipidemia Market Overview at a Glance

6. Dyslipidemia Disease Background and Overview

7. Dyslipidemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Dyslipidemia 

9. Dyslipidemia Current Treatment and Medical Practices

10. Dyslipidemia Unmet Needs

11. Dyslipidemia Emerging Therapies

12. Dyslipidemia Market Outlook

13. Country-Wise Dyslipidemia Market Analysis (2020–2034)

14. Dyslipidemia Market Access and Reimbursement of Therapies

15. Dyslipidemia Market Drivers

16. Dyslipidemia Market Barriers

17.  Dyslipidemia Appendix

18. Dyslipidemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dyslipidemia Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Alnylam Pharma, Amarin Corp, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Merck